An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia.

ABSTRACT:

Background

Data on the long-term efficacy, safety, and tolerability of risperidone in adolescents with schizophrenia are limited. The objective of this study was to evaluate the efficacy and safety of maintenance risperidone treatment in adolescents with schizophrenia.

Methods

This open-label study of adolescents aged 13 to 17 years with schizophrenia was a single extension study of two short-term double-blind risperidone studies and also enrolled subjects directly in open-label risperidone treatment. The risperidone dose was flexible and ranged from 2 to 6 mg/day. Most subjects enrolled for 6 months; a subset enrolled for 12 months. Assessment tools included the Positive and Negative Syndrome Scale total and factor scores, Clinical Global Impressions, Children's Global Asse

SUBMITTER: Pandina G 

PROVIDER: S-EPMC3489792 | biostudies-literature | 2012 Jun

REPOSITORIES: biostudies-literature